| Literature DB >> 33933053 |
Bin Zhou1,2, Lei Zhu2, Cheng Xiang1, Feng Cheng2, Xi Zhu2, Yi Zhou2, Yong Wang3.
Abstract
BACKGROUND: Forearm autotransplantation after parathyroidectomy has turned into the standard method for secondary hyperparathyroidism (SHPT) treatment in chronic kidney disease patients. Our study aimed to explore the effects of three methods including muscle, subcutaneous and muscle + subcutaneous transplant methods on SHPT.Entities:
Keywords: Forearm autotransplantation; Muscle and subcutaneous transplantation; Secondary hyperparathyroidism
Mesh:
Substances:
Year: 2021 PMID: 33933053 PMCID: PMC8088620 DOI: 10.1186/s12893-021-01222-2
Source DB: PubMed Journal: BMC Surg ISSN: 1471-2482 Impact factor: 2.030
Fig. 1SF-36 scores in M + S, M and S groups
Fig. 2Parathyroid pieces preparation. a Four Parathyroid glands were confirmed and dissected b One parathyroid gland was cut into 15 1 × 1 mm pieces
Fig. 3Parathyroid transplant procedure. a M group b S group c M + S group
Preoperative demographic and clinical data of the study participants (n = 75)
| Characteristics | Muscle + subcutaneous | Muscle | Subcutaneous | |
|---|---|---|---|---|
| Sex | ||||
| Male | 11 | 15 | 9 | 0.059 |
| Female | 15 | 20 | 5 | |
| Total | 26 | 35 | 14 | |
| Age (year) | 48.9 ± 9.7 | 48.6 ± 10.7 | 50.0 ± 6.7 | 0.84 |
| Dialysis method | ||||
| Hemodialysis | 15 | 16 | 7 | 0.651 |
| Peritoneal | 11 | 19 | 7 | |
| Duration of dialysis (year) | 5.9 ± 1.6 | 6.4 ± 2.1 | 6.0 ± 2.2 | 0.68 |
| Follow up (Month) | 27.6 ± 3.7 | 28.2 ± 5.2 | 26.3 ± 3.3 | 0.92 |
Biochemical profiles of the patients
| Characteristics | Muscle + subcutaneous | Muscle | Subcutaneous | |
|---|---|---|---|---|
| Calcium (mmol/L) Normal range: 2.05–2.48 | ||||
| Pre-operation | 2.32 ± 0.37 | 2.36 ± 0.27 | 2.27 ± 0.47 | 0.64 |
| Post-operation | 2.15 ± 0.26 | 2.23 ± 0.34 | 2.14 ± 0.39 | 0.72 |
| Phosphate (mmol/L) Normal range: 0.80–1.33 | ||||
| Pre-operation | 2.32 ± 0.26 | 2.33 ± 0.28 | 2.38 ± 0.45 | 0.54 |
| Post-operation | 1.61 ± 0.25 | 1.71 ± 0.17 | 1.64 ± 0.15 | 0.43 |
| PTH (pmol/L) Normal range: 15.00–65.00 | ||||
| Pre-operation | 1336.70 | 1546.60 | 1441.85 | 0.48 |
| Post-operation | 19.800 | 43.300 | 16.600 | 0.04 |
| ALP (U/L) Normal range: 30.00–62.00 | ||||
| Pre-operation | 325.02 ± 57.37 | 298.75 ± 46.28 | 287.25 ± 65.23 | 0.65 |
| Post-operation | 145.63 ± 32.28 | 165.65 ± 43.28 | 165.48 ± 38.35 | 0.13 |
The PTH value was presented as median, and others parameters were presented as means ± standard deviation
Long term profiles after parathyroid gland operation
| Characteristics | 1 month | 2 month | 3 month | 6 month | 12 month | 18 month | 24 month |
|---|---|---|---|---|---|---|---|
| PTH (pmol/L) | |||||||
| Muscle + subcutaneous | 21.000 | 51.100 | 30.500 | 30.700 | 20.800 | 30.200 | 50.600 |
| Muscle | 12.750 | 20.400 | 36.800 | 42.350 | 37.000 | 40.600 | 123.100 |
| Subcutaneous | 20.400 | 32.900 | 61.800 | 47.250 | 49.700 | 55.700 | 65.2000 |
| Calcium (mmol/L) | |||||||
| Muscle + subcutaneous | 1.95 ± 0.24 | 1.98 ± 0.18 | 2.15 ± 0.32 | 2.07 ± 0.23 | 2.13 ± 0.32 | 2.23 ± 0.23 | 2.18 ± 0.42 |
| Muscle | 2.02 ± 0.23 | 2.27 ± 0.34 | 2.26 ± 0.46 | 2.18 ± 0.28 | 2.05 ± 0.21 | 2.28 ± 0.32 | 2.16 ± 0.23 |
| Subcutaneous | 2.13 ± 0.23 | 2.16 ± 0.18 | 2.26 ± 0.32 | 2.23 ± 0.28 | 2.17 ± 0.34 | 2.03 ± 0.23 | 2.13 ± 0.39 |
| Phosphate (mmol/L) | |||||||
| Muscle + subcutaneous | 1.26 ± 0.11 | 1.33 ± 0.18 | 1.41 ± 0.23 | 1.29 ± 0.16 | 1.65 ± 0.17 | 1.57 ± 0.21 | 1.38 ± 0.12 |
| Muscle | 1.43 ± 0.16 | 1.28 ± 0.21 | 1.35 ± 0.18 | 1.38 ± 0.21 | 1.38 ± 0.23 | 1.53 ± 0.18 | 1.43 ± 0.16 |
| Subcutaneous | 1.41 ± 0.21 | 1.23 ± 0.22 | 1.34 ± 0.23 | 1.23 ± 0.14 | 1.43 ± 0.24 | 1.45 ± 0.26 | 1.34 ± 0.21 |
The PTH value was presented as median, and others parameters were presented as means ± standard deviation
Operative symptoms and signs
| Symptoms and signs | Operation methods | Pre-operation | 1 month | 3 month | 6 month | 12 month | 24 month |
|---|---|---|---|---|---|---|---|
| Bone pain | Muscle + subcutaneous | 25 | 18 | 14 | 10 | 8 | 6 |
| Muscle | 33 | 32 | 27 | 22 | 16 | 10 | |
| Subcutaneous | 12 | 10 | 10 | 6 | 4 | 3 | |
| Fracture | Muscle + subcutaneous | 8 | 6 | 6 | 3 | 2 | 0 |
| Muscle | 5 | 4 | 2 | 2 | 2 | 0 | |
| Subcutaneous | 3 | 2 | 2 | 1 | 1 | 0 | |
| Pruritus | Muscle + subcutaneous | 21 | 16 | 12 | 9 | 6 | 3 |
| Muscle | 30 | 27 | 22 | 17 | 14 | 12 | |
| Subcutaneous | 9 | 7 | 4 | 2 | 2 | 1 | |
| Coronary artery calcification | Muscle + subcutaneous | 9 | 3 | 2 | 0 | 0 | 0 |
| Muscle | 12 | 6 | 2 | 1 | 1 | 0 | |
| Subcutaneous | 4 | 3 | 3 | 3 | 2 | 0 |